Skip to main content
Jon Cuthbert Profile pIcture
Jon Cuthbert

Jon Cuthbert

GrafaFounder & COO

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.

Articles by Jon Cuthbert

Grafa

Arrowhead presents expanded patient profile data for cholesterol asset

Arrowhead Pharmaceuticals (NASDAQ:ARWR) unveiled new clinical data expanding the medical profile of plozasiran, its approved RNA interference (RNAi) therapeutic, demonstrating that the drug can be administered to patients suffering from moderate-to-severe renal impairment or moderate hepatic impairment without necessitating a reduction in dose.

Read more: Arrowhead presents expanded patient profile data for cholesterol asset
Grafa

Dyne Therapeutics seeks FDA accelerated approval for muscular dystrophy drug

Dyne Therapeutics (NASDAQ:DYN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking conditional marketing clearance for z-rostudirsen, its investigational treatment targeting a specific subset of patients with Duchenne muscular dystrophy (DMD).

Read more: Dyne Therapeutics seeks FDA accelerated approval for muscular dystrophy drug
Grafa

Biohaven seizure drug extends remission in broad clinical data update

Biohaven (NYSE:BHVN) released new clinical and safety data for opakalim, its selective Kv7.2/7.3 potassium channel activator, showing meaningful reductions in seizure frequency and a highly differentiated central nervous system safety profile across generalized and focal forms of epilepsy.

Read more: Biohaven seizure drug extends remission in broad clinical data update